Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study.

A prospective comparison study across 3 independent research laboratories of a pure IKr blocker E-4031 was conducted by using the same batch of human iPS cell-derived cardiomyocytes in order to verify the utility and reliability of our original standard protocol. Field potential waveforms were recorded with a multi-electrode array system to measure the inter-spike interval and field potential duration. The effects of E-4031 at concentrations of 1 to 100 nM were sequentially examined every 10 min. In each facility, E-4031 significantly prolonged the field potential duration corrected by Fridericia's formula and caused early afterdepolarizations occasionally resulting in triggered activities, whereas it tended to decrease the rate of spontaneous contraction. These results were qualitatively and quantitatively consistent with previous non-clinical in vitro and in vivo studies as well as clinical reports. There were inter-facility differences in some absolute values of the results, which were not observed when the values were normalized as percentage change. Information described in this paper may serve as a guide when predicting the drug-induced repolarization delay and arrhythmias with this new technology of stem cells.

[1]  Kelly Rae Chi Revolution dawning in cardiotoxicity testing , 2013, Nature Reviews Drug Discovery.

[2]  A. V. van Ginneken,et al.  Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. , 1995, Circulation research.

[3]  J. Weiss,et al.  Genesis of Phase 3 Early Afterdepolarizations and Triggered Activity in Acquired Long-QT Syndrome , 2011, Circulation. Arrhythmia and electrophysiology.

[4]  J. Brachmann,et al.  Electrophysiological Effects of E 4031, a Drug with Selective Class III Properties, in Man , 1997, Pacing and clinical electrophysiology : PACE.

[5]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[6]  Thomas Rau,et al.  Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology , 2011, PloS one.

[7]  T. Fujita,et al.  QT/QTc study conducted in Japanese adult healthy subjects: A novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation , 2014, Journal of clinical pharmacology.

[8]  N. Kohmura,et al.  A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  M. Tabo,et al.  Accurate detection of drug-induced delayed ventricular repolarization with a suitable correction formula in Langendorff guinea pig heart. , 2010, The Journal of toxicological sciences.

[10]  H. Inoue,et al.  Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. , 1994, Journal of cardiovascular pharmacology.

[11]  J Jalife,et al.  Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. , 1997, Journal of the American College of Cardiology.

[12]  Keiji Yamamoto,et al.  QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. , 2005, Journal of pharmacological sciences.

[13]  M. Sanguinetti,et al.  Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. , 1991, Circulation research.

[14]  James A Thomson,et al.  Human Embryonic Stem Cells Develop Into Multiple Types of Cardiac Myocytes: Action Potential Characterization , 2003, Circulation research.

[15]  Shinsuke Yuasa,et al.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. , 2009, Biochemical and biophysical research communications.

[16]  J. Brouillette,et al.  Characterization of ventricular repolarization in male and female guinea pigs. , 2007, Journal of molecular and cellular cardiology.

[17]  Ricardo Bolaños,et al.  QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. , 2010, Current drug safety.

[18]  U. Ravens,et al.  Effects of the New Class III Antiarrhythmic Drug E‐4031 on Myocardial Contractility and Electrophysiological Parameters , 1991, Journal of cardiovascular pharmacology.

[19]  G Duker,et al.  Comparison of the IKr blockers moxifloxacin, dofetilide and E‐4031 in five screening models of pro‐arrhythmia reveals lack of specificity of isolated cardiomyocytes , 2012, British journal of pharmacology.

[20]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[21]  Borje Darpo,et al.  THEMED SECTION: QT SAFETY REVIEW The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance , 2010 .